

Global Biomarkers Standardization Consortium (GBSC)

Teleconference Agenda

November 19, 2012

Attendees:

Maria Bjerke
Ingrid Zegers
Manu Vandijck
Heather Snyder
Meredith McNeil
Maria Carrillo
Dean Hartley
Adam Simon

Rand Jenkins
Irina Baburina
Bill Mylott
June Kaplow
Tim West
Henrik Zetterberg
Kaj Blennow
Bob Martone

Glenn Barney
John Lawson
Ian Pike
Vesna Kostanjevecki
Bob Dean
Les Shaw
Diane Stephenson

1. Discussion of progress each lab has made in the development of the 'substitute' or 'surrogate' matrix.

- a. Reviews of each lab's effort on development of surrogate matrix.
 - i. Rat plasma based
No update.
 - ii. BSA & HSA based
Rand gave updated. They are working extensively with five analyte assays using surrogate matrix. There is some concern regarding the concentration of formula and they will follow up with Les Shaw, who is using similar substance. .
 - iii. hCSF based—
Henrik shared they have done a bit of work and recently published a paper on the method using human CSF. This is attached for more information.
 - iv. Analytical parameter evaluations —
Les provided update on their work on the BSA based comparison with CSF based assays. Using the mass spec method, they have done 9 additions of CSF pools to determine the concentration and compared the calibration using BSA matrix to determine concentration. They continue to get excellent correlation across a range of concentration with tight correlation, high R squared. Moving to working on comparing different lots of calibration with their peptide and are just about ready to measure A-beta 38, 40 and 42 in AD verses control individuals.

Overall the groups' efforts are moving forward with developing surrogate or substitute matrix and we will continue updates on future calls.

2. Discuss round robin for 4 laboratories that would include use of a common, agreed on Aβ₁₋₄₂ standard, and internal standard, and aliquots of CSF samples.

Henrik updated on the round robin. There is a drafted project plan for the four laboratories to measure a-β in the same samples. They hope to send the samples by end of year. Proteome Science would like to calibrate and compare their method with the round robin. They can participate now and they will follow up with Henrik/Kaj.

Next meeting, the GBSC will discuss parallel efforts in CSF with tau; Proteome Science will present some of their data.

Ingrid indicated the round robin plan is the type of project that needs to go forward, especially if you can show different quantitative methods are equivalent. We will continue to check in on the activities with Ingrid and her team to ensure we are addressing items needed to be addresses.

Maria gave update on funding for round robin project. There are currently commitments from BMS and from Roche (2-year support) and we are reaching out to a few others. In addition, the Association will also contribute to form a public private partnership.

There was an update on the process for corporations and others to be a part of the IFCC working group. Rand commented that their team is working on the membership application. There needs to be agreements in place in order to move forward. The Association is able to help with the administration of this process, if there is a need.

3. Paul Contestable (JNJ) – Discussion of access of OCD calibrators for assays

Paul was unable to join the discussion, but Irene gave brief update. They are currently working on agreements to share reference materials with IRMM for evaluation. Paul may be able to give an update on the next call in January.

4. Maria Bjerke (Gothenburg University) — Commutability test for A-β

Maria presented the ongoing work on commutability test for A-β (attached presentation).

5. OTHER BUSINESS

Next call is on Monday, January 28 and we will cover five topics:

- Update on the laboratory progress
- OCD calibrators update
- Update on the round robin
- Tau based assays – presentation by Proteome Sciences
- Update on the IFCC workgroup